EMCURE - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.8
| Stock Code | EMCURE | Market Cap | 27,871 Cr. | Current Price | 1,471 ₹ | High / Low | 1,586 ₹ |
| Stock P/E | 41.9 | Book Value | 170 ₹ | Dividend Yield | 0.20 % | ROCE | 13.5 % |
| ROE | 11.6 % | Face Value | 10.0 ₹ | DMA 50 | 1,474 ₹ | DMA 200 | 1,400 ₹ |
| Chg in FII Hold | 0.30 % | Chg in DII Hold | 1.74 % | PAT Qtr | 282 Cr. | PAT Prev Qtr | 118 Cr. |
| RSI | 48.6 | MACD | 6.04 | Volume | 94,626 | Avg Vol 1Wk | 2,08,767 |
| Low price | 889 ₹ | High price | 1,586 ₹ | PEG Ratio | -3.10 | Debt to equity | 0.50 |
| 52w Index | 83.5 % | Qtr Profit Var | 462 % | EPS | 33.7 ₹ | Industry PE | 27.2 |
📊 EMCURE shows good potential for intraday trading today. Momentum indicators (RSI 48.6, MACD 6.04) are moderately positive, and fundamentals are strong with significant quarterly profit growth. However, volume is below the 1-week average, which may limit sharp intraday moves. The stock is trading near its 50 DMA (1,474 ₹), offering a balanced entry point.
💰 Optimal Buy Price: 1,465–1,475 ₹ (near DMA support)
📈 Profit-Taking Exit Levels: 1,495–1,520 ₹ (short-term resistance)
📉 Stop-Loss: 1,450 ₹ (below immediate support)
⏳ If Already Holding: Exit if price fails to sustain above 1,480 ₹ or if intraday volume weakens. Momentum suggests profit booking on rallies rather than holding for extended moves.
✅ Positive
- Strong quarterly PAT growth (282 Cr. vs 118 Cr.).
- EPS at 33.7 ₹ reflects profitability compared to peers.
- ROCE (13.5%) and ROE (11.6%) show healthy returns.
- FII (+0.30%) and DII (+1.74%) holdings increased, reflecting investor confidence.
⚠️ Limitation
- Current price (1,471 ₹) is only marginally above DMA 200 (1,400 ₹), showing limited trend strength.
- Volume (94,626) is significantly below 1-week average (2,08,767), reducing intraday momentum.
- Debt-to-equity ratio at 0.50 is higher than peers, indicating moderate leverage.
- PEG ratio (-3.10) suggests valuation concerns relative to growth.
📉 Company Negative News
- Debt levels slightly elevated compared to industry norms.
- PEG ratio indicates expensive valuation relative to growth trajectory.
📈 Company Positive News
- Quarterly profit variation (+462%) shows strong earnings momentum.
- Dividend yield of 0.20% adds shareholder value.
- Stock has gained 83.5% from its 52-week low, showing resilience.
🏭 Industry
- Industry PE is 27.2, lower than company PE (41.9), indicating EMCURE trades at a premium.
- Pharmaceutical sector outlook remains strong with consistent demand growth.
🔎 Conclusion
EMCURE offers good intraday trading potential with strong fundamentals and positive momentum indicators. Traders may consider entries near support with tight stop-losses and quick profit booking on rallies. Long-term investors may find the stock attractive given its earnings growth and sector strength, though premium valuation and moderate debt warrant caution.